What is Buprenorphine?
DATA Physician Locator
Physician Waiver Qualifications
Waiver Notification Form
Ongoing Web-based Trainings
Waived Physician WebBoard
Update Physician Contact Information
Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports Nurses Guide to Buprenorphine Online Buprenorphine Course for Counselors
The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the Controlled Substances Act. more
PCSSMAT Webinar Series CalendarTo find a schedule of upcoming webinars and listing of available session recordings please view the following link. Webinar Series Calendar.
PCSSMAT Webinar Series March 11
As a partner organization in the SAMHSA-funded Providers’ Clinical Support System for Medication Assisted Treatment, the American Psychiatric Association offers monthly webinars for physicians and other interested clinicians. The sessions are presented by nationally known clinical experts, researchers, and government officials. The next session in the series will take place on Tuesday, March 11, from noon to 1 p.m. Eastern. Elinore McCance-Katz, MD, Chief Medical Officer of SAMHSA, will present Methadone and Buprenorphine: Clinical Impact of Drug Interactions. Registration is now open at www2.gotomeeting.com/register/806461818. CME credit is available without charge.
Treatment Improvement Protocol
Increase Patient Limits
2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program
2006 Report On Diversion and Abuse of Buprenorphine
Drug Enforcement Administraton (DEA)
DATA Physician Locator
Physicians' Clinical Support System-Buprenorphine
CSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program Locator
CSAT Director Advises Physicians of Concerns Regarding Buprenorphine
CSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov
* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.